Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262261 · ClinicalTrials.gov registry record · Phase 3
Re-Treatment Study of Probuphine in Opioid Addiction
A Phase 3 study of Opioid Dependency, sponsored by Titan Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 85
- Enrollment target
- 18
- Study locations
NCT01262261 is a Phase 3 study of Opioid Dependency that has completed, run by Titan Pharmaceuticals. The registered enrollment target is 85 participants. The trial reports 18 study locations across 12 states.
The verdict
NCT01262261, a Phase 3 study of Opioid Dependency, has completed, sponsored by Titan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 85 participants
- Enrollment target
- 18
- Study locations
Study Summary
Probuphine (buprenorphine implant) is an investigational implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This is a 6-month, open-label, re-treatment study that will confirm the safety and efficacy of Probuphine in patients who have previously completed the 6-month PRO-806 study with either Probuphine, placebo or sublingual buprenorphine.
Conditions Studied
Interventions
- DRUG Probuphine (buprenorphine implant)
Study Locations (18)
California
- David Geffen School of Medicine at UCLA - Los Angeles
- Synergy Clinical Research Center - National City
- North County Clinical Research - Oceanside
- Friends Research Institute - Torrance
Florida
- Amit Vijapura, MD - Jacksonville
- Operation PAR, Inc. - TC Campus - Largo
- Fidelity Clinical Research - Lauderhill
- Scientific Clinical Research, Inc. - North Miami
Maryland
- BPRU, Behavioral Biology Research Center - Baltimore
Massachusetts
- Stanley Street Treatment and Resources, Inc - Fall River
Mississippi
- Precise Research Centers - Flowood
Missouri
- Psych Care Consultants Research - St Louis
New York
- St. Luke's Roosevelt Hospital Center - New York
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262261
The ClinicalTrials.gov registry entry for NCT01262261 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Dependency appearing as the primary indexed condition, and to 1 intervention - of which Probuphine (buprenorphine implant) is the first listed.
NCT01262261 reports 18 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT01262261 about?
NCT01262261 is a clinical study titled "Re-Treatment Study of Probuphine in Opioid Addiction". Probuphine (buprenorphine implant) is an investigational implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This is a 6-month, open-label, re-treatment study that will confirm the safety and efficacy of Probuphine in patients who ha...
What is the current status of trial NCT01262261?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 85 participants. The study started on 2010-11. Estimated completion is 2011-11.
What conditions does trial NCT01262261 study?
This clinical trial studies the following conditions: Opioid Dependency.
What interventions are being tested in trial NCT01262261?
The interventions under investigation include: Probuphine (buprenorphine implant) (DRUG).
Who is sponsoring clinical trial NCT01262261?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01262261 being conducted?
This trial has 18 study locations across California, Florida, Maryland, Massachusetts, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Dependency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.